CASSAVA SCIENCES INC (SAVA)

US14817C1071 - Common Stock

4.7099  -21.77 (-82.21%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

CASSAVA SCIENCES INC

NASDAQ:SAVA (11/25/2024, 12:10:10 PM)

4.7099

-21.77 (-82.21%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month21.94%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap225.98M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

SAVA Daily chart

Company Profile

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. The company is headquartered in Austin, Texas and currently employs 29 full-time employees. The company went IPO on 2000-07-14. The firm's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. The company has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease dementia. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. The company is conducting two randomized placebo-controlled Phase III clinical trials of oral simufilam in patients with Alzheimer’s disease dementia. SavaDx, its lead investigational diagnostic product candidate, is a way to detect the presence of Alzheimer’s disease from a small sample of blood. SavaDx is a research-use only, non-safety related exploratory biomarker.

Company Info

CASSAVA SCIENCES INC

6801 N. Capital of Texas Highway, Building 1

Austin TEXAS 78731

P: 15125012444

CEO: Remi Barbier

Employees: 29

Website: https://www.cassavasciences.com/

SAVA News

ChartMill News Image2 hours ago - ChartmillThe market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.

Which stocks are gapping on Monday?

News Image3 hours ago - Investor's Business DailyCassava Sciences Plummets 85% After Embattled Alzheimer's Drug Flops

The company tested simufilam in patients with mild-to-moderate Alzheimer's disease.

ChartMill News Image4 hours ago - ChartmillWhich stocks are moving before the opening bell on Monday?

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

News Image5 hours ago - Cassava Sciences, Inc.Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints
News Image5 hours ago - Cassava Sciences, Inc.Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s disease in...

News Image16 hours ago - Cassava Sciences, Inc.Cassava Sciences to Hold Corporate Update on November 25th

Webcast planned for Monday, November 25th at 8:00 AM ET

SAVA Twits

Here you can normally see the latest stock twits on SAVA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example